Home > Boards > US OTC > Biotechs >

Delcath Systems Inc. (DCTH)

DCTH RSS Feed 		Add DCTH Price Alert      Hide Sticky   Hide Intro
Moderator: CanadaGreece, TheGreatGuy, DesertEagle, Bond, TradedAhead
Search This Board: 
Last Post: 4/22/2019 8:18:06 AM - Followers: 531 - Board type: Free - Posts Today: 2

Web Site: Delcath Systems, Inc.
Stock and Financial Info: OTC Marketplace

About Delcath Systems (OTCQB:DCTH)
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Their proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)-is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company's principal focus is on the treatment of primary and metastatic liver cancers. In the United States, the Melphalan/HDS system is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). The Melphalan/HDS system has not been approved for sale in the United States. In Europe, their proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). In April 2012, they obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT system. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has commenced a global phase 2 clinical trial in Europe to investigate Melphalan/HDS system for primary liver cancer and is initiating plans to evaluate intrahepatic cholangiocarcinoma.
 
Delcath Systems was formed in 1988 as a Pharmaceutical and Medical Device company focused on oncology. The company is registered in Delaware with offices in New York, New York and Manufacturing, Distribution, Research and Development facilities located in Queensbury, New York. The company currently has 10 patents in their US Intellectual Property portfolio according to the US Patent Office.
 
Subsidiaries of Delcath Systems include Delcath Holdings Limited (Ireland), Delcath Systems Limited (Ireland), Delcath Systems B.V. (Netherlands), Delcath Systems Gmbh (Germany) and Delcath Systems UK (United Kingdom).
 
Delcath Systems Securities
Delcath Systems securities originally came on the market on June 16, 2000 with an IPO offering of 1.2m shares priced at $6.00 per share. Securities were listed on both the NASDAQ and Boston Stock Exchange. The stock moved from the NASDAQ to the OTCQB on September 15, 2017 after the company Voluntarily Delisted it from NASDAQ and requested an Accelerated listing in the OTC marketplace.

Stock Split History
The stock has been (reverse) split a total of 4 times. Twice while on the NASDAQ and twice since moving to the OTCQB.
 
The 1st split came on April 9, 2014 at a ratio of 1:16
The 2nd split came on July 21, 2016 at a ratio of 1:16
The 3rd split came on November 6, 2017 at a ratio of 1:350
The 4th split came on May 2, 2018 at a ratio of 1:500

Delcath Share Information
Common Shares Authorized: 1,000,000,000
Preferred Shares Authorized: 10,000,000
Common Shares Outstanding*: 14,998,454 (a/o 4/02/2019)
Preferred Shares Outstanding**: 101 (a/o 12/14/2018) 

Fully Diluted Common Shares as of November 5, 2018 ***


* From SEC 8-K Filing on 04/02/2019 / ** From SEC Filings (Value of Preferred shares is $10,000 per share) / *** From SEC Filings
 
Delcath Systems Clinical Trials
Declcath Systems currently has two clinical trials underway. The first is the FOCUS Trial and the second the ALIGN Trial.
 
The FOCUS Trial is designed to evaluate patients who have melanoma that has spread from the eye to the liver. All patients in the study will be treated with Melphalan/HDS for up to 6 treatments. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment. The FOCUS Trial has an estimated completion date of April 2020. For more info click here  
 
The ALIGN Trial will evaluate two groups of patients who have intrahepatic cholangiocarcinoma. Each group will receive induction treatment with Cisplatin and Gemcitabine per SOC for 4 treatment cycles. Following induction treatment patients will be randomize (1:1), to 2 arms of treatment. One group (50%) will rreceive high dose chemotherapy delivered specifically to the liver, while the other group (50%) will continue treatment with Cisplatin and Gemcitabine. Patient in each group will get repeating cycles of treatment until the cancer advances. All patients will be followed until death. This study will compare the overall survival (OS) in patients with intrahepatic cholangiocarcinoma. The ALIGN Trial has an estimated completion date of January 2023. For more info click here
DCTH
Current Price
Volume:
Bid Ask Day's Range
DCTH Detailed Quote
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
DCTH News: Current Report Filing (8-k) 04/19/2019 04:30:41 PM
DCTH News: Current Report Filing (8-k) 04/16/2019 04:32:58 PM
DCTH News: Current Report Filing (8-k) 04/02/2019 05:30:42 PM
DCTH News: Amended Statement of Ownership (sc 13g/a) 02/14/2019 05:10:21 PM
DCTH News: Current Report Filing (8-k) 02/11/2019 08:19:14 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#48406  Sticky Note My reasons to be skeptical about #Delcath DesertEagle 04/10/19 12:57:07 PM
#48606   Best of luck to all here. benandemmiboo 04/22/19 08:18:05 AM
#48605   Judgement day has arrived Muenster Madness 04/22/19 07:58:48 AM
#48604   I can't predict.that seems steep but who knows.u Turntheship 04/21/19 07:20:35 PM
#48603   One can believe Simpson has done something good SAMNOTSAMUEL 04/21/19 07:11:45 PM
#48602   Also wasnt mediation on 15th.hmmmm.if Friday was Turntheship 04/21/19 05:05:00 PM
#48601   Sammy Jen had 4business days to put 8k Turntheship 04/21/19 05:00:36 PM
#48600   Guys .sinister.maybe they drop it to 5c Turntheship 04/21/19 04:57:08 PM
#48599   Luck james hoped pop would have been 30cto60 Turntheship 04/21/19 04:50:10 PM
#48598   Seems a bit harsh.POSSIBLE.it was 8c b4 Jenny Turntheship 04/21/19 04:43:20 PM
#48597   I expect that completely. However DCTH is Muenster Madness 04/21/19 04:42:56 PM
#48596   GAME OVER!(for retail investor) Bond 04/21/19 02:34:00 PM
#48595   it is really sad part. TheGreatGuy 04/21/19 12:38:47 PM
#48593   Item 2.04. 420man 04/21/19 09:43:13 AM
#48592   I am rather research free on this, but SAMNOTSAMUEL 04/20/19 06:24:17 PM
#48591   why DIDNT she PUT PR OUT RIGHT NOW.WHY Turntheship 04/20/19 06:15:28 PM
#48590   elaborate mr.chairman. Turntheship 04/20/19 06:13:11 PM
#48589   That pr was ethics free, nothing like freedom, NOT SAMNOTSAMUEL 04/20/19 06:00:06 PM
#48588   im looking Thursday ah for a bad filing.NOTHING.wasted Turntheship 04/20/19 05:46:30 PM
#48587   o canada running to dollar range would take Turntheship 04/20/19 05:39:26 PM
#48586   if they did get 7or8 mil upfront its Turntheship 04/20/19 05:37:18 PM
#48585   Looking4BIGcash where are you.please help us from your TheGreatGuy 04/20/19 02:35:07 PM
#48584   If DGF will dilute theirs 54 million warrants TheGreatGuy 04/20/19 02:33:09 PM
#48583   Read it again. Not the case. CanadaGreece 04/20/19 07:01:25 AM
#48582   It read to me that someone else was Thudmother 04/19/19 10:08:56 PM
#48581   James we have come to expect Friday ah Turntheship 04/19/19 08:52:27 PM
#48580   We really don't know what they have to Turntheship 04/19/19 08:46:55 PM
#48579   it makes no sense why medac has anything SAMNOTSAMUEL 04/19/19 07:22:07 PM
#48578   1.No 10 k.2.in court case TO survive ,3.in Turntheship 04/19/19 06:45:34 PM
#48577   Listen to ANOTHER 8K FILED LATE ON A Turntheship 04/19/19 06:39:25 PM
#48576   Even on a day mkt closed they Turntheship 04/19/19 06:34:56 PM
#48575   Unfortunately it makes no sense. Not a Muenster Madness 04/19/19 06:21:00 PM
#48574   On April 15, 2019, Delcath Systems, Inc. (the Lwe6638 04/19/19 06:03:15 PM
#48573   Another 8K just out. http://delcath.com/sec-filings/ Thudmother 04/19/19 05:57:36 PM
#48572   Sammy and latest press release say potential dilution SAMNOTSAMUEL 04/19/19 05:27:00 PM
#48571   Dr. Peddar has been left Delcath. 250 million TheGreatGuy 04/19/19 04:37:50 PM
#48570   DCTH Delcath Systems, Inc. Delcath Investor Presentation https://www.otcmarkets MyzStreet 04/19/19 04:15:49 PM
#48569   Show your true colors it’s good. ;) MyzStreet 04/19/19 04:15:18 PM
#48568   There was less of fud before 8k with Turntheship 04/19/19 03:25:20 PM
#48567   As sammy said mkt cap is a trap Turntheship 04/19/19 03:21:47 PM
#48566   Just mixing in some positive with all the MyzStreet 04/19/19 01:53:50 PM
#48565   Hhhaaaaa great pumping.Most of retails are already burned.We TheGreatGuy 04/19/19 01:47:30 PM
#48564   There are 2 ideas: court case and medac SAMNOTSAMUEL 04/19/19 01:39:16 PM
#48563   For a bit sure. There’s risk still super MyzStreet 04/19/19 12:49:37 PM
#48562   In case you didn't know, if they lose CanadaGreece 04/19/19 12:44:19 PM
#48561   Sideline sitters. Roflmao sure ya all are but MyzStreet 04/19/19 12:38:56 PM
#48560   Surely revenue in Europe is getting beyond predictability SAMNOTSAMUEL 04/19/19 12:10:10 PM
#48559   Keep it up. Clap clap clap.. ;) MyzStreet 04/19/19 11:07:13 AM
#48558   Thank the 8k no money.court case no filing . Turntheship 04/19/19 11:02:11 AM
#48557   With this market cap I’ll gather what I MyzStreet 04/19/19 10:41:04 AM
#48556   This could pop nicely on anything to hang SAMNOTSAMUEL 04/18/19 11:23:09 AM
PostSubject
© 2019 InvestorsHub.com, Inc.




Ticker News is disabled